Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Thyroid Gland Hurthle Cell Carcinoma”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Testing effectiveness (Phase 2)Study completedNCT00098813
What this trial is testing

Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine

Who this might be right for
Recurrent Thyroid CancerStage IV Follicular Thyroid CancerStage IV Papillary Thyroid Cancer
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03914300
What this trial is testing

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Gland CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaPoorly Differentiated Thyroid Gland Carcinoma+6 more
National Cancer Institute (NCI) 11
Testing effectiveness (Phase 2)Study completedNCT02973997
What this trial is testing

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Who this might be right for
Columnar Cell Variant Thyroid Gland Papillary CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaMetastatic Thyroid Gland Follicular Carcinoma+23 more
Academic and Community Cancer Research United 57
Testing effectiveness (Phase 2)Study completedNCT01811212
What this trial is testing

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Who this might be right for
Poorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaStage I Thyroid Gland Follicular Carcinoma+13 more
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)Looking for participantsNCT06959641
What this trial is testing

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

Who this might be right for
Locally Advanced Differentiated Thyroid Gland CarcinomaLocally Advanced Poorly Differentiated Thyroid Gland CarcinomaLocally Advanced Thyroid Gland Follicular Carcinoma+18 more
Northwestern University 33
Early research (Phase 1)Study completedNCT05410821
What this trial is testing

Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer

Who this might be right for
Refractory Thyroid Gland CarcinomaRefractory Thyroid Gland Papillary CarcinomaRefractory Thyroid Gland Follicular Carcinoma+1 more
The First Affiliated Hospital of Xiamen University 12
Testing effectiveness (Phase 2)Study completedNCT00381641
What this trial is testing

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Who this might be right for
Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaRefractory Thyroid Gland Carcinoma+16 more
National Cancer Institute (NCI) 63
Testing effectiveness (Phase 2)Active Not RecruitingNCT04544111
What this trial is testing

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Who this might be right for
Thyroid CancerThyroid Cancer, FollicularPapillary Thyroid Cancer+4 more
Memorial Sloan Kettering Cancer Center 19
Testing effectiveness (Phase 2)Study completedNCT01208051
What this trial is testing

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Who this might be right for
Refractory Differentiated Thyroid Gland CarcinomaRefractory Thyroid Gland Follicular CarcinomaRefractory Thyroid Gland Hurthle Cell Carcinoma+2 more
National Cancer Institute (NCI) 127